Multi-center, randomized, double-blind, placebo-controlled, exploratory study to evaluate the efficacy and safety of HAD-B1 for dose-finding in EGFR positive and locally advanced or metastatic NSCLC subjects who need Afatinib therapy: Study protocol clinical trial (SPIRIT Compliant)

BACKGROUND: In recent studies, afatinib, a second-generation inhibitor, showed superior outcomes, when compared to the first-generation of EGFR-tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib, in patients with advanced non-small cell lung cancer (NSCLC) harboring mutations of epid...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, So-Jung, Kang, Hwi-Joong, Jun, Hyung-Joon, Shin, Seong-Hoon, Yoo, Hwa-Seung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
3800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004641/
https://www.ncbi.nlm.nih.gov/pubmed/31977865
http://dx.doi.org/10.1097/MD.0000000000018735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004641/
https://www.ncbi.nlm.nih.gov/pubmed/31977865
http://dx.doi.org/10.1097/MD.0000000000018735

Ejemplares similares